5:56 AM
Apr 30, 2019
 |  BC Innovations  |  Distillery Therapeutics

Syntrix's dual CXCR1/CXCR2 inhibitor for combos in oral, lung cancers


INDICATION: Lung cancer; solid tumors

Mouse studies suggest combining the dual CXCR1/CXCR2 inhibitor SX-682 with anti-PD-1 mAbs or T cell therapies could help treat oral and lung cancers. In mouse models of oral carcinoma and Lewis lung carcinoma...

Read the full 179 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >